Testosterone is used to treat low testosterone levels in men, helping to restore energy, muscle strength, and sexual function. It can also be used in hormone therapy for transgender individuals.[2] Andriol is currently approved and in use across 62 indications[4].[1]
Andriol is one of 1123 small molecule programs targeting Insulin resistance. It is currently in Approved.
Indications
Total Trials
Active Trials
Competitors
FDA Applications
NDA/BLA/ANDA regulatory filings
Patents
Pipeline
Competition
2828 competitors in Breast Cancer
Andriol
Cymbalta
MS Contin
Recentin
Spravato
Avastin
Nubain
Fentanyl Citrate
Beta Blocker
Metfomin
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Regulatory
Oct 12, 1993
TESTODERM
NDA NDA019762
Dec 18, 1997
TESTODERM TTS
NDA NDA020791
Oct 31, 2002
TESTIM
NDA NDA021454
Jun 19, 2003
STRIANT
NDA NDA021543
Sep 26, 2003
ANDROGEL
NDA NDA021015
Nov 23, 2010
AXIRON
NDA NDA022504
Dec 29, 2010
FORTESTA
NDA NDA021463
Apr 29, 2011
ANDROGEL
NDA NDA022309
Oct 20, 2011
ANDRODERM
NDA NDA020489
Feb 14, 2012
TESTOSTERONE
NDA NDA202763
Jan 31, 2013
TESTOSTERONE
NDA NDA203098
May 28, 2014
NATESTO
NDA NDA205488
Jun 4, 2014
VOGELXO
NDA NDA204399
Sources